A safer cannabinoid receptor blocker enhanced weight loss from semaglutide, tirzepatide, and liraglutide by up to 50% in obese mice, achieving 32.6% body weight reduction when combined with tirzepatide.
-32.6% body weight with CRB-913 + tirzepatideCombining CRB-913 with tirzepatide achieved the largest weight reduction among all combinations, surpassing either drug alone and reaching levels of weight loss previously only seen with bariatric surgery.
What the researchers found
CRB-913, a novel cannabinoid receptor 1 (CB1R) inverse agonist with 9.5-fold lower brain penetration than rimonabant, enhanced the weight loss effects of three GLP-1 peptide drugs in obese mice. Combinations produced body weight reductions of -32.6% with tirzepatide, -28.8% with semaglutide, and -16.8% with liraglutide by day 18. CRB-913 alone achieved -22% weight loss. Combinations also improved body fat content, liver triglycerides, and liver fat deposits. CRB-913's reduced brain penetration aims to avoid the psychiatric side effects that derailed the original CB1R blocker rimonabant.
Why it matters
Even the most effective GLP-1 drugs don't achieve sufficient weight loss for all patients. This study demonstrates that combining GLP-1 peptide agonists with a peripheral CB1R blocker can dramatically enhance weight loss beyond what either approach achieves alone. By designing CRB-913 to stay out of the brain, the researchers addressed the safety concerns that killed rimonabant — potentially unlocking an entire drug class for combination with peptide therapies.
The numbers in context
CRB-913 alone: -22% body weight · + tirzepatide: -32.6% · + semaglutide: -28.8% · + liraglutide: -16.8% · 18-day treatment · 3.8-fold greater plasma exposure vs rimonabant · 9.5-fold lower brain levels vs rimonabant
How the study worked
CRB-913 was pharmacokinetically characterized and compared to rimonabant for plasma exposure and brain penetration. Dose-response was tested as monotherapy in diet-induced obese (DIO) mice. Combination studies tested CRB-913 (2.5 mg/kg) with tirzepatide, semaglutide, or liraglutide in DIO mice over 18 days. Body weight, body fat content, liver triglycerides, and liver fat deposits were measured.
Who was studied
Diet-induced obese (DIO) mice treated with CRB-913 alone or in combination with GLP-1 peptide drugs
What this study cannot tell us
This is a mouse study, and weight loss in DIO mice may not directly predict human outcomes. The 18-day treatment period is short — long-term efficacy and safety of the combination are unknown. While CRB-913 has reduced brain penetration, it is not zero — potential psychiatric effects in humans need evaluation. The specific mechanism of synergy between CB1R blockade and GLP-1 RA signaling was not fully elucidated.
How to read the evidence
This is a preclinical study in diet-induced obese mice. While the results are compelling and the pharmacokinetic improvements over rimonabant are well-characterized, translation to human efficacy and safety requires clinical trials.
When this study was published
Published in 2023, this study is recent and reflects the current trend toward combination obesity therapies and the ongoing effort to unlock peripherally restricted CB1R blockers.
The bigger picture
The obesity drug field is increasingly moving toward combination therapies, recognizing that targeting multiple pathways simultaneously produces better results. This study validates a particularly promising combination: GLP-1 peptide agonists (which reduce appetite centrally) plus peripheral CB1R blockade (which may improve metabolic function in fat and liver tissue). If CRB-913's safety profile holds up in humans, it could become a powerful addition to existing GLP-1 drug regimens.
Questions still open
- Will the enhanced weight loss from CRB-913 + GLP-1 RA combinations persist with longer treatment durations?
- Is CRB-913's brain penetration low enough to completely avoid psychiatric side effects seen with rimonabant?
- Could CRB-913 reduce the dose of GLP-1 RA needed, thereby improving tolerability and reducing gastrointestinal side effects?
Common questions
Why was the original cannabinoid blocker rimonabant pulled from the market?
How does blocking cannabinoid receptors enhance GLP-1 drug effects?
Read the original research
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model.
Obesity (Silver Spring, Md.), 31(11), 2676-2688
Citation
Morningstar, Marshall; Kolodziej, Andrew; Ferreira, Suzie; Blumen, Tracy; Brake, Rachael; Cohen, Yuval. (2023). Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model.. Obesity (Silver Spring, Md.), 31(11), 2676-2688. https://doi.org/10.1002/oby.23902